. Author manuscript; available in PMC: 2015 Jun 1.

Published in final edited form as: Biol Blood Marrow Transplant. 2014 Feb 16;20(6):787–793. doi: 10.1016/j.bbmt.2014.02.010

Table 3. Cox regression analysis of no or low (< 10,000 copies/mL, n = 74) versus high (≥ 10,000 copies/mL, n = 51) peak viremia within the first 100 days and transplant outcomes (n = 125).

	Sustained Engraftment^* at 100 Days		Day 100 II-IV aGVHD	Day 100 TRM	1-Yr DFS
	Neutrophils	Platelets	Day 100 II-IV aGVHD	Day 100 TRM	1-Yr DFS
HR for ≥ 10,000 Viremia (95% CI)	0.98 (0.68-1.41)	1.01 (0.68-1.50)	1.41 (0.86-2.31)	1.04 (0.51-2.13)	0.71 (0.39-1.30)
P value	0.92	0.95	0.17	0.90	0.27

aGVHD indicates acute graft-versus-host disease; TRM, transplant related mortality; DFS, disease free survival; HR, hazard ratio; CI, confidence interval.

Estimate incorporates speed and success of neutrophil and platelet engraftment (speed and success).